SK9862003A3 - A drug for the treatment of osteonecrosis and for the management of patients at risk of developing osteonecrosis - Google Patents

A drug for the treatment of osteonecrosis and for the management of patients at risk of developing osteonecrosis Download PDF

Info

Publication number: SK9862003A3
Authority: SK; Slovakia
Prior art keywords: bisphosphonate; medicament; ester; pharmaceutically acceptable; acceptable salt
Prior art date: 2001-02-06

Application number

SK986-2003A

Other languages

English (en)

Slovak (sk)

Inventor

David G Little

Nicholas Charles Smith

Original Assignee

Royal Alexandra Hosp Children

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-02-06

Filing date

2001-12-13

Publication date

2004-02-03

2001-02-06 Priority claimed from AUPR2907A external-priority patent/AUPR290701A0/en

2001-04-03 Priority claimed from AUPR4187A external-priority patent/AUPR418701A0/en

2001-07-27 Priority claimed from AUPR6654A external-priority patent/AUPR665401A0/en

2001-12-13 Application filed by Royal Alexandra Hosp Children filed Critical Royal Alexandra Hosp Children

2004-02-03 Publication of SK9862003A3 publication Critical patent/SK9862003A3/sk

Links

206010031264 Osteonecrosis Diseases 0.000 title claims abstract description 82
239000003814 drug Substances 0.000 title claims abstract description 81
238000011282 treatment Methods 0.000 title claims abstract description 35
229940079593 drug Drugs 0.000 title abstract description 19
229940122361 Bisphosphonate Drugs 0.000 claims abstract description 91
150000004663 bisphosphonates Chemical class 0.000 claims abstract description 87
201000010099 disease Diseases 0.000 claims abstract description 17
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 17
210000000988 bone and bone Anatomy 0.000 claims description 84
150000002148 esters Chemical class 0.000 claims description 43
150000003839 salts Chemical class 0.000 claims description 43
201000009859 Osteochondrosis Diseases 0.000 claims description 40
238000000034 method Methods 0.000 claims description 40
208000007656 osteochondritis dissecans Diseases 0.000 claims description 31
229960004276 zoledronic acid Drugs 0.000 claims description 25
XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical group OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 claims description 24
108090000623 proteins and genes Proteins 0.000 claims description 16
208000027414 Legg-Calve-Perthes disease Diseases 0.000 claims description 15
210000000689 upper leg Anatomy 0.000 claims description 13
VMMKGHQPQIEGSQ-UHFFFAOYSA-N minodronic acid Chemical compound C1=CC=CN2C(CC(O)(P(O)(O)=O)P(O)(O)=O)=CN=C21 VMMKGHQPQIEGSQ-UHFFFAOYSA-N 0.000 claims description 12
229950011129 minodronic acid Drugs 0.000 claims description 12
OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 claims description 11
229940062527 alendronate Drugs 0.000 claims description 11
230000006378 damage Effects 0.000 claims description 11
WRUUGTRCQOWXEG-UHFFFAOYSA-N pamidronate Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 claims description 11
229940046231 pamidronate Drugs 0.000 claims description 11
238000002054 transplantation Methods 0.000 claims description 11
210000000845 cartilage Anatomy 0.000 claims description 10
102000004169 proteins and genes Human genes 0.000 claims description 10
MPBVHIBUJCELCL-UHFFFAOYSA-N Ibandronate Chemical compound CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O MPBVHIBUJCELCL-UHFFFAOYSA-N 0.000 claims description 9
229940015872 ibandronate Drugs 0.000 claims description 9
DBVJJBKOTRCVKF-UHFFFAOYSA-N Etidronic acid Chemical compound OP(=O)(O)C(O)(C)P(O)(O)=O DBVJJBKOTRCVKF-UHFFFAOYSA-N 0.000 claims description 8
IIDJRNMFWXDHID-UHFFFAOYSA-N Risedronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CC1=CC=CN=C1 IIDJRNMFWXDHID-UHFFFAOYSA-N 0.000 claims description 8
ACSIXWWBWUQEHA-UHFFFAOYSA-N clodronic acid Chemical compound OP(O)(=O)C(Cl)(Cl)P(O)(O)=O ACSIXWWBWUQEHA-UHFFFAOYSA-N 0.000 claims description 8
LWRDQHOZTAOILO-UHFFFAOYSA-N incadronic acid Chemical compound OP(O)(=O)C(P(O)(O)=O)NC1CCCCCC1 LWRDQHOZTAOILO-UHFFFAOYSA-N 0.000 claims description 8
229950006971 incadronic acid Drugs 0.000 claims description 8
230000000921 morphogenic effect Effects 0.000 claims description 8
229940089617 risedronate Drugs 0.000 claims description 8
DKJJVAGXPKPDRL-UHFFFAOYSA-N Tiludronic acid Chemical compound OP(O)(=O)C(P(O)(O)=O)SC1=CC=C(Cl)C=C1 DKJJVAGXPKPDRL-UHFFFAOYSA-N 0.000 claims description 7
UGEPSJNLORCRBO-UHFFFAOYSA-N [3-(dimethylamino)-1-hydroxy-1-phosphonopropyl]phosphonic acid Chemical compound CN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O UGEPSJNLORCRBO-UHFFFAOYSA-N 0.000 claims description 7
229960002286 clodronic acid Drugs 0.000 claims description 7
229940009626 etidronate Drugs 0.000 claims description 7
PUUSSSIBPPTKTP-UHFFFAOYSA-N neridronic acid Chemical compound NCCCCCC(O)(P(O)(O)=O)P(O)(O)=O PUUSSSIBPPTKTP-UHFFFAOYSA-N 0.000 claims description 7
229950010733 neridronic acid Drugs 0.000 claims description 7
229940019375 tiludronate Drugs 0.000 claims description 7
-1 zoledronic acid bisphosphonate Chemical class 0.000 claims description 7
239000003102 growth factor Substances 0.000 claims description 6
238000004519 manufacturing process Methods 0.000 claims description 6
210000004233 talus Anatomy 0.000 claims description 6
239000004606 Fillers/Extenders Substances 0.000 claims description 5
230000006837 decompression Effects 0.000 claims description 5
210000001137 tarsal bone Anatomy 0.000 claims description 5
210000000707 wrist Anatomy 0.000 claims description 5
206010058112 Chondrolysis Diseases 0.000 claims description 4
101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 claims description 3
101001076292 Homo sapiens Insulin-like growth factor II Proteins 0.000 claims description 3
102100037852 Insulin-like growth factor I Human genes 0.000 claims description 3
102100025947 Insulin-like growth factor II Human genes 0.000 claims description 3
102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 3
108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 3
230000000735 allogeneic effect Effects 0.000 claims description 3
210000001872 metatarsal bone Anatomy 0.000 claims description 3
ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims description 3
210000002303 tibia Anatomy 0.000 claims description 3
102000007350 Bone Morphogenetic Proteins Human genes 0.000 claims description 2
108010007726 Bone Morphogenetic Proteins Proteins 0.000 claims description 2
102000018233 Fibroblast Growth Factor Human genes 0.000 claims description 2
108050007372 Fibroblast Growth Factor Proteins 0.000 claims description 2
229940112869 bone morphogenetic protein Drugs 0.000 claims description 2
229940126864 fibroblast growth factor Drugs 0.000 claims description 2
210000002758 humerus Anatomy 0.000 claims description 2
102000008137 Bone Morphogenetic Protein 4 Human genes 0.000 claims 2
108010049955 Bone Morphogenetic Protein 4 Proteins 0.000 claims 2
102000003971 Fibroblast Growth Factor 1 Human genes 0.000 claims 2
108090000386 Fibroblast Growth Factor 1 Proteins 0.000 claims 2
IWLDTXOHXPDPQG-UHFFFAOYSA-L disodium;hydroxy-[1-hydroxy-1-[hydroxy(oxido)phosphoryl]-3-pyrrolidin-1-ylpropyl]phosphinate Chemical compound [Na+].[Na+].OP(=O)(O)C(P([O-])([O-])=O)(O)CCN1CCCC1 IWLDTXOHXPDPQG-UHFFFAOYSA-L 0.000 claims 2
229940029303 fibroblast growth factor-1 Drugs 0.000 claims 2
101150061927 BMP2 gene Proteins 0.000 claims 1
102100024785 Fibroblast growth factor 2 Human genes 0.000 claims 1
108090000379 Fibroblast growth factor 2 Proteins 0.000 claims 1
101150067309 bmp4 gene Proteins 0.000 claims 1
230000008468 bone growth Effects 0.000 claims 1
230000011164 ossification Effects 0.000 description 20
206010017076 Fracture Diseases 0.000 description 16
208000010392 Bone Fractures Diseases 0.000 description 15
239000002253 acid Substances 0.000 description 12
238000001356 surgical procedure Methods 0.000 description 12
241000700159 Rattus Species 0.000 description 11
230000000694 effects Effects 0.000 description 9
230000001338 necrotic effect Effects 0.000 description 9
241001465754 Metazoa Species 0.000 description 8
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
210000002745 epiphysis Anatomy 0.000 description 8
210000002436 femur neck Anatomy 0.000 description 8
210000004394 hip joint Anatomy 0.000 description 8
239000011780 sodium chloride Substances 0.000 description 8
210000004027 cell Anatomy 0.000 description 7
210000001188 articular cartilage Anatomy 0.000 description 5
230000036407 pain Effects 0.000 description 5
206010028980 Neoplasm Diseases 0.000 description 4
241000906034 Orthops Species 0.000 description 4
208000014674 injury Diseases 0.000 description 4
201000008482 osteoarthritis Diseases 0.000 description 4
238000004321 preservation Methods 0.000 description 4
239000000047 product Substances 0.000 description 4
208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 3
208000007848 Alcoholism Diseases 0.000 description 3
241000131317 Capitulum Species 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
206010023204 Joint dislocation Diseases 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
208000027418 Wounds and injury Diseases 0.000 description 3
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
230000036770 blood supply Effects 0.000 description 3
239000000316 bone substitute Substances 0.000 description 3
201000011510 cancer Diseases 0.000 description 3
231100000433 cytotoxic Toxicity 0.000 description 3
230000001472 cytotoxic effect Effects 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
239000003862 glucocorticoid Substances 0.000 description 3
210000004349 growth plate Anatomy 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
230000007774 longterm Effects 0.000 description 3
239000001301 oxygen Substances 0.000 description 3
229910052760 oxygen Inorganic materials 0.000 description 3
238000004393 prognosis Methods 0.000 description 3
238000011321 prophylaxis Methods 0.000 description 3
230000004044 response Effects 0.000 description 3
239000000126 substance Substances 0.000 description 3
238000002560 therapeutic procedure Methods 0.000 description 3
238000011541 total hip replacement Methods 0.000 description 3
230000000472 traumatic effect Effects 0.000 description 3
208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 2
206010002091 Anaesthesia Diseases 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
208000023275 Autoimmune disease Diseases 0.000 description 2
208000030016 Avascular necrosis Diseases 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 2
229930105110 Cyclosporin A Natural products 0.000 description 2
108010036949 Cyclosporine Proteins 0.000 description 2
206010011951 Decompression Sickness Diseases 0.000 description 2
206010013654 Drug abuse Diseases 0.000 description 2
208000015872 Gaucher disease Diseases 0.000 description 2
208000023661 Haematological disease Diseases 0.000 description 2
206010019663 Hepatic failure Diseases 0.000 description 2
241000283973 Oryctolagus cuniculus Species 0.000 description 2
229920000954 Polyglycolide Polymers 0.000 description 2
208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
208000001647 Renal Insufficiency Diseases 0.000 description 2
206010001584 alcohol abuse Diseases 0.000 description 2
208000025746 alcohol use disease Diseases 0.000 description 2
230000037005 anaesthesia Effects 0.000 description 2
238000000540 analysis of variance Methods 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
230000033115 angiogenesis Effects 0.000 description 2
210000003423 ankle Anatomy 0.000 description 2
230000008901 benefit Effects 0.000 description 2
230000033558 biomineral tissue development Effects 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
210000001185 bone marrow Anatomy 0.000 description 2
238000010322 bone marrow transplantation Methods 0.000 description 2
238000007469 bone scintigraphy Methods 0.000 description 2
DEGAKNSWVGKMLS-UHFFFAOYSA-N calcein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(O)=O)CC(O)=O)=C(O)C=C1OC1=C2C=C(CN(CC(O)=O)CC(=O)O)C(O)=C1 DEGAKNSWVGKMLS-UHFFFAOYSA-N 0.000 description 2
OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
239000004568 cement Substances 0.000 description 2
210000003679 cervix uteri Anatomy 0.000 description 2
229960001265 ciclosporin Drugs 0.000 description 2
235000019504 cigarettes Nutrition 0.000 description 2
210000003109 clavicle Anatomy 0.000 description 2
239000003246 corticosteroid Substances 0.000 description 2
229960001334 corticosteroids Drugs 0.000 description 2
229930182912 cyclosporin Natural products 0.000 description 2
208000030172 endocrine system disease Diseases 0.000 description 2
239000007850 fluorescent dye Substances 0.000 description 2
239000012634 fragment Substances 0.000 description 2
239000000499 gel Substances 0.000 description 2
230000014509 gene expression Effects 0.000 description 2
230000035876 healing Effects 0.000 description 2
210000001624 hip Anatomy 0.000 description 2
230000001506 immunosuppresive effect Effects 0.000 description 2
230000001939 inductive effect Effects 0.000 description 2
210000003734 kidney Anatomy 0.000 description 2
201000006370 kidney failure Diseases 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
208000032839 leukemia Diseases 0.000 description 2
239000007788 liquid Substances 0.000 description 2
210000004185 liver Anatomy 0.000 description 2
208000007903 liver failure Diseases 0.000 description 2
231100000835 liver failure Toxicity 0.000 description 2
210000004072 lung Anatomy 0.000 description 2
230000036210 malignancy Effects 0.000 description 2
239000013521 mastic Substances 0.000 description 2
235000015097 nutrients Nutrition 0.000 description 2
229960002378 oftasceine Drugs 0.000 description 2
210000000056 organ Anatomy 0.000 description 2
230000000399 orthopedic effect Effects 0.000 description 2
210000000963 osteoblast Anatomy 0.000 description 2
210000002997 osteoclast Anatomy 0.000 description 2
230000008506 pathogenesis Effects 0.000 description 2
210000004560 pineal gland Anatomy 0.000 description 2
239000004633 polyglycolic acid Substances 0.000 description 2
230000002265 prevention Effects 0.000 description 2
230000000750 progressive effect Effects 0.000 description 2
230000000069 prophylactic effect Effects 0.000 description 2
238000011084 recovery Methods 0.000 description 2
239000011347 resin Substances 0.000 description 2
229920005989 resin Polymers 0.000 description 2
230000000250 revascularization Effects 0.000 description 2
238000012552 review Methods 0.000 description 2
208000007056 sickle cell anemia Diseases 0.000 description 2
230000000391 smoking effect Effects 0.000 description 2
210000004872 soft tissue Anatomy 0.000 description 2
239000000243 solution Substances 0.000 description 2
239000003351 stiffener Substances 0.000 description 2
210000005065 subchondral bone plate Anatomy 0.000 description 2
208000011117 substance-related disease Diseases 0.000 description 2
230000002195 synergetic effect Effects 0.000 description 2
230000009885 systemic effect Effects 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
229950003937 tolonium Drugs 0.000 description 2
HNONEKILPDHFOL-UHFFFAOYSA-M tolonium chloride Chemical compound [Cl-].C1=C(C)C(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 HNONEKILPDHFOL-UHFFFAOYSA-M 0.000 description 2
125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
229920002972 Acrylic fiber Polymers 0.000 description 1
108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 description 1
208000006386 Bone Resorption Diseases 0.000 description 1
206010070918 Bone deformity Diseases 0.000 description 1
206010065687 Bone loss Diseases 0.000 description 1
102100024506 Bone morphogenetic protein 2 Human genes 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
206010010356 Congenital anomaly Diseases 0.000 description 1
241000699800 Cricetinae Species 0.000 description 1
201000003883 Cystic fibrosis Diseases 0.000 description 1
JVTAAEKCZFNVCJ-UWTATZPHSA-N D-lactic acid Chemical compound C[C@@H](O)C(O)=O JVTAAEKCZFNVCJ-UWTATZPHSA-N 0.000 description 1
FMTDIUIBLCQGJB-UHFFFAOYSA-N Demethylchlortetracyclin Natural products C1C2C(O)C3=C(Cl)C=CC(O)=C3C(=O)C2=C(O)C2(O)C1C(N(C)C)C(O)=C(C(N)=O)C2=O FMTDIUIBLCQGJB-UHFFFAOYSA-N 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
206010061209 Hip deformity Diseases 0.000 description 1
206010020649 Hyperkeratosis Diseases 0.000 description 1
YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
206010028851 Necrosis Diseases 0.000 description 1
102000004067 Osteocalcin Human genes 0.000 description 1
108090000573 Osteocalcin Proteins 0.000 description 1
208000002804 Osteochondritis Diseases 0.000 description 1
208000001132 Osteoporosis Diseases 0.000 description 1
229930040373 Paraformaldehyde Natural products 0.000 description 1
208000020201 Primary bone dysplasia Diseases 0.000 description 1
241000700157 Rattus norvegicus Species 0.000 description 1
208000008877 Shoulder Dislocation Diseases 0.000 description 1
206010072610 Skeletal dysplasia Diseases 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
201000007930 alcohol dependence Diseases 0.000 description 1
230000001772 anti-angiogenic effect Effects 0.000 description 1
230000000123 anti-resoprtive effect Effects 0.000 description 1
238000013459 approach Methods 0.000 description 1
210000001367 artery Anatomy 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
239000010836 blood and blood product Substances 0.000 description 1
229940125691 blood product Drugs 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
230000018678 bone mineralization Effects 0.000 description 1
230000024279 bone resorption Effects 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
230000024245 cell differentiation Effects 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
230000008859 change Effects 0.000 description 1
208000018805 childhood acute lymphoblastic leukemia Diseases 0.000 description 1
201000011633 childhood acute lymphocytic leukemia Diseases 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
238000002648 combination therapy Methods 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
230000006835 compression Effects 0.000 description 1
238000007906 compression Methods 0.000 description 1
208000018631 connective tissue disease Diseases 0.000 description 1
238000011393 cytotoxic chemotherapy Methods 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
FMTDIUIBLCQGJB-SEYHBJAFSA-N demeclocycline Chemical compound C1([C@@H](O)[C@H]2C3)=C(Cl)C=CC(O)=C1C(=O)C2=C(O)[C@@]1(O)[C@@H]3[C@H](N(C)C)C(O)=C(C(N)=O)C1=O FMTDIUIBLCQGJB-SEYHBJAFSA-N 0.000 description 1
229960002398 demeclocycline Drugs 0.000 description 1
238000013461 design Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
230000003292 diminished effect Effects 0.000 description 1
238000005553 drilling Methods 0.000 description 1
238000009547 dual-energy X-ray absorptiometry Methods 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
125000000219 ethylidene group Chemical group [H]C(=[*])C([H])([H])[H] 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
208000020089 femoral neck fracture Diseases 0.000 description 1
238000000799 fluorescence microscopy Methods 0.000 description 1
238000001215 fluorescent labelling Methods 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
229910052588 hydroxylapatite Inorganic materials 0.000 description 1
238000002639 hyperbaric oxygen therapy Methods 0.000 description 1
238000010191 image analysis Methods 0.000 description 1
125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 description 1
239000003018 immunosuppressive agent Substances 0.000 description 1
229940124589 immunosuppressive drug Drugs 0.000 description 1
230000001976 improved effect Effects 0.000 description 1
230000006872 improvement Effects 0.000 description 1
230000006698 induction Effects 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
238000007689 inspection Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
208000028867 ischemia Diseases 0.000 description 1
210000000281 joint capsule Anatomy 0.000 description 1
230000008407 joint function Effects 0.000 description 1
229960003299 ketamine Drugs 0.000 description 1
238000002372 labelling Methods 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
210000003141 lower extremity Anatomy 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
230000003211 malignant effect Effects 0.000 description 1
238000007726 management method Methods 0.000 description 1
239000000463 material Substances 0.000 description 1
238000002483 medication Methods 0.000 description 1
239000011707 mineral Substances 0.000 description 1
239000000203 mixture Substances 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
230000017074 necrotic cell death Effects 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
230000001582 osteoblastic effect Effects 0.000 description 1
230000002018 overexpression Effects 0.000 description 1
229920002866 paraformaldehyde Polymers 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
230000007170 pathology Effects 0.000 description 1
239000008188 pellet Substances 0.000 description 1
XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
238000003359 percent control normalization Methods 0.000 description 1
239000002831 pharmacologic agent Substances 0.000 description 1
238000011422 pharmacological therapy Methods 0.000 description 1
238000011458 pharmacological treatment Methods 0.000 description 1
238000005498 polishing Methods 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
229910021426 porous silicon Inorganic materials 0.000 description 1
230000008092 positive effect Effects 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000002243 precursor Substances 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
208000034133 primary 1 avascular necrosis of femoral head Diseases 0.000 description 1
208000037920 primary disease Diseases 0.000 description 1
230000008569 process Effects 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
238000001959 radiotherapy Methods 0.000 description 1
230000009467 reduction Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
206010039073 rheumatoid arthritis Diseases 0.000 description 1
208000037921 secondary disease Diseases 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
238000010186 staining Methods 0.000 description 1
210000000130 stem cell Anatomy 0.000 description 1
239000013589 supplement Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
238000012353 t test Methods 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
238000012546 transfer Methods 0.000 description 1
230000008733 trauma Effects 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
230000002792 vascular Effects 0.000 description 1
230000003966 vascular damage Effects 0.000 description 1
239000013598 vector Substances 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
229960001600 xylazine Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1841—Transforming growth factor [TGF]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
- A61L2300/414—Growth factors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/02—Materials or treatment for tissue regeneration for reconstruction of bones; weight-bearing implants

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Immunology (AREA)
Bioinformatics & Cheminformatics (AREA)
Zoology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biomedical Technology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Molecular Biology (AREA)
Developmental Biology & Embryology (AREA)
Cell Biology (AREA)
Rheumatology (AREA)
Transplantation (AREA)
Virology (AREA)
Biotechnology (AREA)
Dermatology (AREA)
Oral & Maxillofacial Surgery (AREA)
Hematology (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Surgery (AREA)
Pain & Pain Management (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

SK986-2003A 2001-02-06 2001-12-13 A drug for the treatment of osteonecrosis and for the management of patients at risk of developing osteonecrosis SK9862003A3 (en)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
AUPR2907A AUPR290701A0 (en)	2001-02-06	2001-02-06	A drug for the treatment of osteonecrosis and for the management of patients at risk of developing osteonecrosis
AUPR4187A AUPR418701A0 (en)	2001-04-03	2001-04-03	A drug for use in bone grafting
AUPR6654A AUPR665401A0 (en)	2001-07-27	2001-07-27	A drug and method for the treatment of osteonecrosis
PCT/AU2001/001616 WO2002062351A1 (en)	2001-02-06	2001-12-13	A drug for the treatment of osteonecrosis and for the management of patients at risk of developing osteonecrosis

Publications (1)

Publication Number	Publication Date
SK9862003A3 true SK9862003A3 (en)	2004-02-03

Family

ID=27158265

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK986-2003A SK9862003A3 (en)	2001-02-06	2001-12-13	A drug for the treatment of osteonecrosis and for the management of patients at risk of developing osteonecrosis

Country Status (23)

Country	Link
US (2)	US7425549B2 (pl)
EP (1)	EP1365769B1 (pl)
JP (1)	JP2004527479A (pl)
KR (1)	KR20030072399A (pl)
CN (1)	CN1233325C (pl)
AT (1)	ATE496624T1 (pl)
AU (1)	AU2002221339B2 (pl)
BR (1)	BR0116862A (pl)
CA (1)	CA2435552C (pl)
CY (1)	CY1111402T1 (pl)
CZ (1)	CZ301361B6 (pl)
DE (1)	DE60143964D1 (pl)
DK (1)	DK1365769T3 (pl)
HU (1)	HUP0303013A3 (pl)
IL (1)	IL157201A (pl)
MX (1)	MXPA03007029A (pl)
NO (1)	NO20033446L (pl)
NZ (1)	NZ527351A (pl)
PL (1)	PL361909A1 (pl)
SI (1)	SI1365769T1 (pl)
SK (1)	SK9862003A3 (pl)
WO (1)	WO2002062351A1 (pl)
ZA (1)	ZA200305890B (pl)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK1365769T3 (da) *	2001-02-06	2011-05-16	Sydney Children S Hospitals Network Randwick And Westmead Incorporating The Royal Alexandra Hospital	Lægemiddel til behandling af osteonekrose og til behandling af patienter med risiko for at udvikle osteonekrose
AU2002244520B2 (en) *	2001-04-03	2007-05-24	The Royal Alexandra Hospital For Children	A drug for use in bone grafting
CA2469779C (en) *	2001-12-21	2008-02-12	The Procter & Gamble Company	Method for the treatment of bone disorders
CN1939314A (zh)	2002-05-10	2007-04-04	弗·哈夫曼-拉罗切有限公司	用于治疗和预防骨质疏松症的二膦酸
SI1596870T2 (sl) *	2002-12-20	2011-07-29	Hoffmann La Roche	Formulacija z visokim odmerkom ibandronata
ATE342722T1 (de)	2003-05-07	2006-11-15	Osteologix As	Behandlung von knorpel/knochen-erkrankungen mit wasserlöslichen strontiumsalzen
JPWO2005072747A1 (ja) *	2004-02-02	2007-09-13	小野薬品工業株式会社	骨吸収抑制剤
ITMI20040218A1 (it) *	2004-02-10	2004-05-10	Abiogen Pharma Spa	Uso di neridronato sodico per promuovere la neoformazione ossea
PL1732575T3 (pl)	2004-02-26	2011-05-31	Osteologix As	Związki zawierające stron do stosowania w zapobieganiu lub leczeniu stanów nekrotycznych kości
EP1802641B8 (en) *	2004-10-08	2012-03-07	The Board Of Trustees Of The University Of Illinois	Bisphosphonate compounds and methods for bone resorption diseases, cancer, bone pain, immune disorders, and infectious diseases
US8012949B2 (en) *	2004-10-08	2011-09-06	The Board Of Trustees Of The University Of Illinois	Bisphosphonate compounds and methods with enhanced potency for multiple targets including FPPS, GGPPS, and DPPS
WO2006050493A2 (en) *	2004-11-03	2006-05-11	The Regents Of The University Of Michigan	Biodegradable implant for intertransverse process fusion
US8071574B2 (en) *	2005-02-22	2011-12-06	John Dennis Bobyn	Implant improving local bone formation
JP2009530414A (ja) *	2006-03-17	2009-08-27	ザボードオブトラスティーズオブザユニヴァーシティーオブイリノイ	ビスホスホネート化合物及び方法
US7833270B2 (en) *	2006-05-05	2010-11-16	Warsaw Orthopedic, Inc	Implant depots to deliver growth factors to treat osteoporotic bone
US8062364B1 (en)	2007-04-27	2011-11-22	Knee Creations, Llc	Osteoarthritis treatment and device
US20160016982A1 (en)	2009-07-31	2016-01-21	Thar Pharmaceuticals, Inc.	Crystallization method and bioavailability
EP2459176B1 (en)	2009-07-31	2017-09-27	Grünenthal GmbH	Crystallization method and bioavailability
US9169279B2 (en)	2009-07-31	2015-10-27	Thar Pharmaceuticals, Inc.	Crystallization method and bioavailability
US9340565B2 (en)	2010-11-24	2016-05-17	Thar Pharmaceuticals, Inc.	Crystalline forms
GB201200868D0 (en) *	2012-01-19	2012-02-29	Depuy Int Ltd	Bone filler composition
CA2928350C (en) *	2013-10-25	2018-01-09	Antecip Bioventures Ii Llc	Compositions for oral administration of zoledronic acid or related compounds for treating disease
WO2015200032A1 (en)	2014-06-25	2015-12-30	Spine Wave, Inc.	Minimally invasive posterolateral fusion
CN105012995B (zh) *	2015-06-04	2018-03-09	武汉维斯第医用科技股份有限公司	一种含促骨愈合药物的胶原蛋白海绵及其制备方法
WO2016204711A1 (en)	2015-06-16	2016-12-22	Spine Wave, Inc.	Instrument and system for placing graft, implant and graft material for minimally invasive posterolateral fusion
AU2017207449A1 (en) *	2016-01-14	2018-08-09	The Regents Of The University Of California	Methods of treating osteonecrosis with LLP2A-bisphosphonate compounds
US10195218B2 (en)	2016-05-31	2019-02-05	Grunenthal Gmbh	Crystallization method and bioavailability
AU2017204355B2 (en)	2016-07-08	2021-09-09	Mako Surgical Corp.	Scaffold for alloprosthetic composite implant

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH08505142A (ja)	1992-12-23	1996-06-04	メルクエンドカンパニーインコーポレーテッド	骨損失を治療及び予防するためのビスホスホネート／エストロゲン療法
US5403829A (en) *	1993-03-24	1995-04-04	Leiras Oy	Use of bisphosphonates in endo-osteal bone surgery
US5646134A (en)	1994-04-21	1997-07-08	Merck & Co., Inc.	Alendronate therapy to prevent loosening of, or pain associated with, orthopedic implant devices
US5476865A (en) *	1994-07-06	1995-12-19	Eli Lilly And Company	Methods of inhibiting bone loss
CN1113440A (zh)	1994-07-29	1995-12-20	孟照强	一种治疗骨伤的中药制剂及其制备方法
WO1996039974A1 (en) *	1995-06-07	1996-12-19	Implex Corporation	Femoral head core channel filling prosthesis
US7041641B2 (en)	1997-03-20	2006-05-09	Stryker Corporation	Osteogenic devices and methods of use thereof for repair of endochondral bone and osteochondral defects
US5843678A (en) *	1997-04-16	1998-12-01	Amgen Inc.	Osteoprotegerin binding proteins
US6316408B1 (en)	1997-04-16	2001-11-13	Amgen Inc.	Methods of use for osetoprotegerin binding protein receptors
EP1027076A2 (de)	1997-10-29	2000-08-16	University Of Pittsburgh Of The Commonwealth System Of Higher Education	Verwendung von vektoren wie adenoviren und/oder adeno-assoziierten viren und/oder retroviren und/oder herpes-simplex-viren und/oder liposomen und/oder plasmiden als vehikel für genetische information zur befähigung von säugetierzellen mittel, zur behandlung von knochenpathologien zu produzieren
US6268367B1 (en) *	1998-02-23	2001-07-31	Zymogenetics, Inc.	Piperazine derivatives for treating bone deficit conditions
EP1121133A1 (en)	1998-10-15	2001-08-08	Merck & Co., Inc.	Methods for stimulating bone formation
PT1178810E (pt) *	1999-05-21	2005-08-31	Novartis Ag	Utilizacao de acidos bisfosfonicos para o tratamento de angiogenese
AU781068B2 (en) *	1999-08-19	2005-05-05	Sydney Children's Hospitals Network (Randwick and Westmead) (incorporating The Royal Alexandra Hospital for Children), The	Drug for treating fractures
AUPQ232599A0 (en)	1999-08-19	1999-09-09	Royal Alexandra Hospital For Children, The	Drug for treating fractures
WO2001016180A2 (en) *	1999-08-27	2001-03-08	Board Of Regents, The University Of Texas System	Cd40 agonist compositions and methods of use
GB0029111D0 (en)	2000-11-29	2001-01-10	Novartis Ag	Organic compounds
DK1365769T3 (da) *	2001-02-06	2011-05-16	Sydney Children S Hospitals Network Randwick And Westmead Incorporating The Royal Alexandra Hospital	Lægemiddel til behandling af osteonekrose og til behandling af patienter med risiko for at udvikle osteonekrose
AUPR553701A0 (en)	2001-06-07	2001-07-12	Royal Alexandra Hospital For Children, The	A device for the delivery of a drug to a fractured bone

2001
- 2001-12-13 DK DK01273650.0T patent/DK1365769T3/da active
- 2001-12-13 WO PCT/AU2001/001616 patent/WO2002062351A1/en not_active Ceased
- 2001-12-13 KR KR10-2003-7010328A patent/KR20030072399A/ko not_active Ceased
- 2001-12-13 US US10/470,924 patent/US7425549B2/en not_active Expired - Fee Related
- 2001-12-13 CA CA2435552A patent/CA2435552C/en not_active Expired - Fee Related
- 2001-12-13 DE DE60143964T patent/DE60143964D1/de not_active Expired - Lifetime
- 2001-12-13 NZ NZ527351A patent/NZ527351A/en not_active IP Right Cessation
- 2001-12-13 CN CNB018225365A patent/CN1233325C/zh not_active Expired - Fee Related
- 2001-12-13 SI SI200130991T patent/SI1365769T1/sl unknown
- 2001-12-13 CZ CZ20032408A patent/CZ301361B6/cs not_active IP Right Cessation
- 2001-12-13 PL PL36190901A patent/PL361909A1/pl not_active IP Right Cessation
- 2001-12-13 AU AU2002221339A patent/AU2002221339B2/en not_active Ceased
- 2001-12-13 MX MXPA03007029A patent/MXPA03007029A/es active IP Right Grant
- 2001-12-13 SK SK986-2003A patent/SK9862003A3/sk unknown
- 2001-12-13 BR BR0116862-2A patent/BR0116862A/pt not_active Application Discontinuation
- 2001-12-13 EP EP01273650A patent/EP1365769B1/en not_active Expired - Lifetime
- 2001-12-13 HU HU0303013A patent/HUP0303013A3/hu unknown
- 2001-12-13 AT AT01273650T patent/ATE496624T1/de active
- 2001-12-13 JP JP2002562358A patent/JP2004527479A/ja active Pending
2003
- 2003-07-30 ZA ZA2003/05890A patent/ZA200305890B/en unknown
- 2003-07-31 IL IL157201A patent/IL157201A/en not_active IP Right Cessation
- 2003-08-04 NO NO20033446A patent/NO20033446L/no not_active Application Discontinuation
2008
- 2008-08-13 US US12/191,264 patent/US7612050B2/en not_active Expired - Fee Related
2011
- 2011-04-20 CY CY20111100406T patent/CY1111402T1/el unknown

Also Published As

Publication number	Publication date
CN1529604A (zh)	2004-09-15
JP2004527479A (ja)	2004-09-09
NZ527351A (en)	2005-01-28
CA2435552C (en)	2010-04-27
HUP0303013A2 (hu)	2003-12-29
EP1365769B1 (en)	2011-01-26
ZA200305890B (en)	2005-01-26
EP1365769A4 (en)	2005-08-10
EP1365769A1 (en)	2003-12-03
CN1233325C (zh)	2005-12-28
WO2002062351A1 (en)	2002-08-15
ATE496624T1 (de)	2011-02-15
HUP0303013A3 (en)	2007-06-28
HK1061797A1 (en)	2004-10-08
US20090005347A1 (en)	2009-01-01
CZ20032408A3 (cs)	2004-06-16
KR20030072399A (ko)	2003-09-13
CY1111402T1 (el)	2015-08-05
NO20033446D0 (no)	2003-08-04
IL157201A (en)	2010-04-29
NO20033446L (no)	2003-10-01
US7612050B2 (en)	2009-11-03
CZ301361B6 (cs)	2010-01-27
CA2435552A1 (en)	2002-08-15
PL361909A1 (pl)	2004-10-04
US20040097469A1 (en)	2004-05-20
BR0116862A (pt)	2004-01-13
SI1365769T1 (sl)	2011-06-30
DK1365769T3 (da)	2011-05-16
AU2002221339B2 (en)	2006-04-27
DE60143964D1 (de)	2011-03-10
US7425549B2 (en)	2008-09-16
MXPA03007029A (es)	2004-10-15

Legal Events

Date

Code

Title

Description

2011-02-04

TC4A

Change of owner's name

Owner name: THE SYDNEY CHILDREN S HOSPITALS NETWORK (RANDW, AU

Effective date: 20101213

2013-02-04

FB9A

Suspension of patent application procedure

Publication	Publication Date	Title
SK9862003A3 (en)	2004-02-03	A drug for the treatment of osteonecrosis and for the management of patients at risk of developing osteonecrosis
AU2002221339A1 (en)	2003-02-13	A drug for the treatment of osteonecrosis and for the management of patients at risk of developing osteonecrosis
RU2161032C2 (ru)	2000-12-27	Использование бисфосфонатов для ингибирования резорбции кости, возникающей вследствие имплантации ортопедических протезов
AU2002244520B2 (en)	2007-05-24	A drug for use in bone grafting
AU2002244520A1 (en)	2003-04-10	A drug for use in bone grafting
WO2002098307A1 (en)	2002-12-12	A device for the delivery of a drug to a fractured bone
JP2026041714A (ja)	2026-03-10	人工骨膜
Tekin et al.	2008	Effects of alendronate on rate of distraction in rabbit mandibles
RU2284821C2 (ru)	2006-10-10	Лекарственное средство для лечения остеонекроза и для лечения пациентов с риском развития остеонекроза
ES2362024T3 (es)	2011-06-27	Fármaco para el tratamiento de osteonecrosis para la gestión de pacientes con riesgo de desarrollar osteonecrosis.
HK1061797B (en)	2011-10-07	A drug for the treatment of osteonecrosis and for the management of patients at risk of developing osteonecrosis
Chapman	2023	Effects of Systemically Administered Mes-1022 in Rats with a Critical-Size Femoral Segmental Defect